Intentional internal high-dose policy in VMAT for stage III NSCLC with consolidation durvalumab: a retrospective study

BACKGROUND: Concurrent chemoradiotherapy followed by durvalumab is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, uniform radiation dose escalation has failed to improve outcomes due to increased toxicity. The intentional internal high dose policy (IIHDP...

詳細記述

書誌詳細

主要な著者:	Kae Okuma, Tairo Kashihara, Yuko Nakayama, Koji Inaba, Tomoya Kaneda, Kana Takahashi, Madoka Sakuramachi, Ayaka Nagao, Akane Yoshiba, Hiroshi Igaki
フォーマット:	Artigo
言語:	Inglês
出版事項:	Via Medica 2026-02-01
シリーズ:	Reports of Practical Oncology and Radiotherapy
主題:	NSCLC intentional internal high dose policy (IIHDP) volumetric modulated arc therapy (VMAT) durvalumab radiation dose escalation local control toxicity
オンライン･アクセス:	https://journals.viamedica.pl/rpor/article/view/110097
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!